Hagop Youssoufian

Dr. Youssoufian served as Chief Medical Officer at BIND Therapeutics. Prior to BIND, he was Executive Vice President at Progenics Pharmaceuticals and President, Research & Development, and Chief Medical Officer at Ziopharm Oncology. Before joining Ziopharm, Dr. Youssoufian served as Chief Medical Officer and Senior Vice President, Global Clinical Sciences at Imclone Systems. Prior to Imclone, he served in leadership positions at Sanofi Aventis and Bristol-Myers Squibb. Earlier in his career in the industry, Dr. Youssoufian was involved in the development and approval of several oncology treatments, including Sprycel®, Taxotere®, and Erbitux®. Dr. Youssoufian graduated from Boston College (BS, magna cum laude) and the University of Massachusetts Medical School (MSc, MD). After training in Internal Medicine at Cleveland Clinic and Johns Hopkins, he completed fellowships in Clinical Genetics at Johns Hopkins and in Hematology-Oncology at Massachusetts General Hospital and was a Visiting Scientist at Whitehead Institute, MIT. He then served on the faculties of Harvard Medical School as Assistant Professor of Medicine and at Baylor College of Medicine as Associate Professor and Division Chief of Medical Genetics.